- Home
- Publications
- Publication Search
- Publication Details
Title
The role of IDH mutations in acute myeloid leukemia
Authors
Keywords
-
Journal
Future Oncology
Volume 14, Issue 10, Pages 979-993
Publisher
Future Medicine Ltd
Online
2018-03-15
DOI
10.2217/fon-2017-0523
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia
- (2018) Mark A. Gregory et al. EXPERIMENTAL HEMATOLOGY
- Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency
- (2017) Diego Avellaneda Matteo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
- (2017) Kenneth F. Bradstock et al. JOURNAL OF CLINICAL ONCOLOGY
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Influence of IDH on FLT3-ITD status in newly diagnosed AML
- (2017) P Boddu et al. LEUKEMIA
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
- (2017) Jacob L. Glass et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
- (2016) M. R. Luskin et al. BLOOD
- Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
- (2016) K. H. Metzeler et al. BLOOD
- Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
- (2016) Satoshi Inoue et al. CANCER CELL
- Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
- (2016) O. Clark et al. CLINICAL CANCER RESEARCH
- Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
- (2016) K.C. Birendra et al. Clinical Lymphoma Myeloma & Leukemia
- Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
- (2016) Héléna Boutzen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Frequent reconstitution of IDH2R140Q mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia
- (2016) D H Wiseman et al. LEUKEMIA
- Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
- (2016) A Chaturvedi et al. LEUKEMIA
- Subtype-specific patterns of molecular mutations in acute myeloid leukemia
- (2016) D Rose et al. LEUKEMIA
- DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
- (2016) Olga A Guryanova et al. NATURE MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- MutantIDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation
- (2016) Francine E Garrett-Bakelman et al. Epigenomics
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
- (2016) Polina Matre et al. Oncotarget
- The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
- (2016) Jing-Yi Chen et al. Scientific Reports
- Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations
- (2015) Yang Xu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
- (2015) Courtney D. DiNardo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
- (2015) Ashkan Emadi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
- (2015) N. Jacque et al. BLOOD
- The importance of plasma D-2HG measurement in screening forIDHmutations in acute myeloid leukaemia
- (2015) Elizabeth McGehee et al. BRITISH JOURNAL OF HAEMATOLOGY
- IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia
- (2015) Y. Ogawara et al. CANCER RESEARCH
- DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia
- (2015) A. R. Sehgal et al. CLINICAL CANCER RESEARCH
- Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients
- (2015) Salah Aref et al. Clinical Lymphoma Myeloma & Leukemia
- Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2015) Mia Y. Platt et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy
- (2015) D H Wiseman et al. LEUKEMIA
- Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
- (2015) J Balss et al. LEUKEMIA
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
- (2015) R J Molenaar et al. LEUKEMIA
- Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
- (2015) S Jilg et al. LEUKEMIA
- IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
- (2015) C D DiNardo et al. LEUKEMIA
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia
- (2015) Amir T. Fathi et al. SEMINARS IN HEMATOLOGY
- The alternative role of DNA methylation in splicing regulation
- (2015) Galit Lev Maor et al. TRENDS IN GENETICS
- IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
- (2015) Houria Debarri et al. Oncotarget
- IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
- (2015) Philipp Kickingereder et al. Scientific Reports
- Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis
- (2015) Thomas McKerrell et al. Cell Reports
- IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
- (2014) A. Kernytsky et al. BLOOD
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
- (2014) J. E. Lancet et al. BLOOD
- Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
- (2014) L. I. Kroeze et al. BLOOD
- Genetic alterations of the cohesin complex genes in myeloid malignancies
- (2014) S. Thota et al. BLOOD
- IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
- (2014) A. R. Grassian et al. CANCER RESEARCH
- Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
- (2014) Lev M. Kats et al. Cell Stem Cell
- IDH1andIDH2mutations confer an adverse effect in patients with acute myeloid leukemia lacking theNPM1mutation
- (2014) Shunichiro Yamaguchi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner
- (2014) GUOLIANG WANG et al. Molecular Medicine Reports
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
- (2014) Liran I. Shlush et al. NATURE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis
- (2014) Jie Jin et al. PLoS One
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
- (2014) M. R. Corces-Zimmerman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
- (2013) Alan R. Rendina et al. BIOCHEMISTRY
- Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
- (2013) O. Abdel-Wahab et al. BLOOD
- Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
- (2013) A. Chaturvedi et al. BLOOD
- Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications
- (2013) F. Thol et al. BLOOD
- Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
- (2013) C. D. DiNardo et al. BLOOD
- R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis
- (2013) Dan Ye et al. CANCER CELL
- TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS
- (2013) Rachel Deplus et al. EMBO JOURNAL
- Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
- (2013) Ashkan Emadi et al. EXPERIMENTAL HEMATOLOGY
- Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
- (2013) C. Chen et al. GENES & DEVELOPMENT
- Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
- (2013) Maxime Janin et al. JOURNAL OF CLINICAL ONCOLOGY
- Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals
- (2013) Ruichuan Yin et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases
- (2013) E Solary et al. LEUKEMIA
- Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy
- (2013) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Lack of association ofIDH1, IDH2andDNMT3Amutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
- (2013) Courtney D. DiNardo et al. LEUKEMIA & LYMPHOMA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
- (2013) J.-H. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
- (2012) A. T. Fathi et al. BLOOD
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure
- (2012) Thomas Prébet et al. BRITISH JOURNAL OF HAEMATOLOGY
- Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance
- (2012) Yuejun Fu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- TET2 promotes histone O-GlcNAcylation during gene transcription
- (2012) Qiang Chen et al. NATURE
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
- (2012) Tino Schenk et al. NATURE MEDICINE
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
- (2012) Marta Fernandez-Mercado et al. PLoS One
- The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
- (2011) C. L. Green et al. BLOOD
- Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin
- (2011) Farhad Ravandi et al. CANCER
- TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis
- (2011) Cyril Quivoron et al. CANCER CELL
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation
- (2011) Kelly Moran-Crusio et al. CANCER CELL
- Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond
- (2011) Junjie U. Guo et al. CELL CYCLE
- A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
- (2011) M. Lubbert et al. HAEMATOLOGICA
- Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission
- (2011) W-C Chou et al. LEUKEMIA
- Reductive carboxylation supports growth in tumour cells with defective mitochondria
- (2011) Andrew R. Mullen et al. NATURE
- Metabolism unhinged: IDH mutations in cancer
- (2011) John R Prensner et al. NATURE MEDICINE
- Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice
- (2011) M. Ko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of -ketoglutarate to citrate to support cell growth and viability
- (2011) D. R. Wise et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acute Myeloid Leukemia WithIDH1orIDH2Mutation
- (2010) Keyur P. Patel et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
- (2010) S. Abbas et al. BLOOD
- Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
- (2010) B. Falini et al. BLOOD
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
- (2010) H. Kantarjian et al. BLOOD
- Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
- (2010) Julien Rocquain et al. BMC CANCER
- IDH1 and IDH2: Not Your Typical Oncogenes
- (2010) Zachary J. Reitman et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
- (2010) Maria E. Figueroa et al. CANCER CELL
- Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H
- (2010) Bei Yang et al. CELL RESEARCH
- Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
- (2010) Katharina Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2010) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
- (2010) Myunggon Ko et al. NATURE
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
- (2009) Amanda F. Cashen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search